Imagine your child scratching herself so unstoppably through the night that she wakes with blood-stained sheets. Nothing soothes her. You haven’t slept through the night in years. At school, unable to focus, she takes off her shoes and socks to scratch her feet on the carpet. The itch is inescapable. She has a life-threatening liver disease, and it’s getting worse.
Now imagine that you work for a company with a chance to help this child and her family.
This is Albireo. We are relentlessly focused on liver disease with the belief that bile acid modulation offers an innovative way to treat numerous rare and more common diseases affecting people worldwide. We are building a collaborative, committed, employee-friendly company, as we work to make this vision a reality.
Albireo is a public clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat rare childhood liver disease and other liver or gastrointestinal diseases and disorders. Albireo has deep expertise in bile acid biology and a clinical pipeline of three mid to late-stage product candidates designed to act locally to restore normal bile acid levels and treat diseases associated with irregularities in bile acid biology.
Albireo’s lead program is developing a therapy to treat patients with Progressive Familial Intrahepatic Cholestasis (PFIC). The Company initiated its global phase 3 study of A4250 in patients with PFIC in 2018 and expects topline results in mid-2020, with a projected potential first regulatory approval and launch in 2021.
Albireo was spun out from AstraZeneca in 2008 and is led by Ron Cooper, Albireo’s first President & CEO. Ron Cooper is a global P&L leader who joined Albireo after a distinguished career at Bristol Myers Squibb, including serving as BMS’s President of Europe, where he was responsible for 30 countries and sales exceeding $4.5B.
Albireo is located in Boston, Massachusetts (Financial District), and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.
Job Title: Director, Clinical Quality Assurance
Reports To: Director of Quality Assurance
Location: Boston, MA
The Director of Clinical Quality plays a lead role in the development of the operational strategy to ensure clinical studies are conducted in a compliant manner and data integrity is maintained. The Director leads and facilitates operational and continuous improvement of Albireo’s Clinical Quality systems. The Director will create a strategic oversight plan, develop standards, create processes and work with Clinical Operations and Contract Research Organizations (CRO) to establish efficient risk-based quality systems that allow fast and flexible compliant development activities.
The Director will additionally assist in monitoring adherence to regulatory requirements (ICH, FDA, EMA, etc.) and GCP guidelines. He/She leads efforts to identify potential compliance and operational risks to Albireo clinical trials and facilitate the development of mitigation strategies with the assistance of Clinical Development and QA personnel. The goal is to assure the high quality of our operations and services aiming to the long-term success of our business.
Key Duties and Responsibilities:
Minimum Education, Experience, Knowledge and Skills Required:
Equal Opportunity Employer
All applicants should be legally entitled to work for any employer in the U.S.
Note to employment agencies: Please do not forward any agency resumes.